SCHEMBL19974699

SCHEMBL19974699

CC(N)C(O)C(=O)NCC1CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.48
KMT2A Q03164 2/20 0.40
TSHR P16473 1/20 0.38
METAP2 P50579 1/20 0.38
ANPEP P15144 1/20 0.38
DNPEP Q9ULA0 1/20 0.38
ARG1 P05089 4/20 0.36
REN P00797 1/20 0.36
CYP2D6 P10635 1/20 0.36
F10 P00742 2/20 0.36
PRSS1 P07477 2/20 0.36
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36
APH1B Q8WW43 1/20 0.36
NCSTN Q92542 1/20 0.36
APH1A Q96BI3 1/20 0.36
PSENEN Q9NZ42 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
ARG2 P78540 1/20 0.35
EPHX1 P07099 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19974929 0.91 METAP2 (0.48) TDP1KMT2ATSHRMETAP2REN
SCHEMBL19975154 0.86 TDP1 (0.46) TDP1KMT2ATSHRMETAP2ANPEP
SCHEMBL8239366 0.82 TDP1 (0.54) TDP1KMT2ATSHRARG1CYP2D6
SCHEMBL28655000 0.82 TDP1 (0.54) TDP1KMT2ATSHRARG1CYP2D6
SCHEMBL28654997 0.82 TDP1 (0.54) TDP1KMT2ATSHRARG1CYP2D6
SCHEMBL19974900 0.82 METAP2 (0.46) TDP1KMT2ATSHRMETAP2ANPEP
SCHEMBL28316928 0.80 TDP1 (0.50) TDP1KMT2ATSHRCYP2D6SMN1; SMN2
SCHEMBL19975390 0.80 TDP1 (0.42) TDP1KMT2ATSHRF10PRSS1
SCHEMBL8012947 0.80 METAP2 (0.44) TDP1KMT2ATSHRMETAP2REN
SCHEMBL19975180 0.80 TDP1 (0.47) TDP1KMT2ATSHRMETAP2ANPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
CN-110062753-A Antiviral compounds 哈普洛根有限责任公司 2019-07-26 CN disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
EP-3512836-A1 ANTIVIRAL COMPOUNDS Haplogen GmbH (AT) 2019-07-24 EP disclosed
WO-2018050631-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C TDP1 1016/4885KMT2A 4031/4885TSHR 4378/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C TDP1 911/4885KMT2A 4177/4885TSHR 4240/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C TDP1 1016/4885KMT2A 4031/4885TSHR 4378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.